Cipla Ltd has received tentative approval from the U.S. Food and Drug Administration for granisetron hydrochloride tablets
Cipla Ltd has received tentative approval from the U.S. Food and Drug Administration for granisetron hydrochloride tablets. The drug is indicated for prevention of nausea and vomiting caused by chemotherapy and radiation in the treatment of cancer.
The Company's products include anti-asthmatics, anti-cancer, anti-inflammatory, anti-depressant and other therapeutic index including animal health care products. The Company also provides technology services for preparation of product, product and process know how and new developments. Its manufacturing facilities are located in Maharashtra, Karnataka, Goa and Himachal Pradesh. The products of the Company are sold in India, Africa, Middle East, Europe, America, Asia and Australia.